Entries by Louise Mason

Mission and AbbVie’s Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Milestone

3rd December 2019 in /by

CAMBRIDGE, UK – 3 December 2019 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), and AbbVie (“AbbVie”)(NYSE: ABBV), a global, research-driven biopharmaceutical company, today announced the identification of several DUBs as potential drug targets in their Alzheimer’s and Parkinson’s R&D collaboration. AbbVie has nominated the panel […]

Mission Therapeutics’ Collaboration with AbbVie Nominated for Scrip Best Partnership Alliance Award

16th September 2019 in /by

CAMBRIDGE, UK – 16 September 2019 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), announced today that its collaboration with research-based global biopharmaceutical company, AbbVie (“AbbVie”)(NYSE: ABBV), has been shortlisted for the 2019 Scrip Best Partnership Alliance Award. Mission and AbbVie are working together in the […]

Dr. James Summers Appointed to Mission Therapeutics’ Board of Directors

1st May 2019 in /by

CAMBRIDGE, UK – 1 May 2019 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), today announced the appointment of Dr. James Summers as an independent member to its Board of Directors, with immediate effect. Dr. Summers brings over […]

Dr Nick Edmunds Appointed to VP, Head of DUB Discovery

3rd December 2018 in /by

CAMBRIDGE, UK – 3 December 2018 –Mission Therapeutics, a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Nick Edmunds as Vice President, Head of DUB Discovery, with immediate effect. Dr Edmunds has over 15 years’ pharmaceutical industry experience and a […]

Mission Therapeutics and AbbVie sign DUBs Collaboration in Alzheimer’s and Parkinson’s Disease

15th November 2018 in /by

Collaboration combines Mission’s unique science, chemistry and proprietary enzyme platform with AbbVie’s strong neurodegenerative disease research, development and commercialisation capabilities CAMBRIDGE, UK and NORTH CHICAGO, ILL, USA – 15th November 2018 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) and AbbVie (“AbbVie”)(NYSE: ABBV), a research-based global […]

Mission Therapeutics Strengthens Clinical Development Team with Appointment of Dr Judit Molnar as Senior Director, Translational Medicine

4th September 2018 in /by

CAMBRIDGE, UK – 4 September 2018 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat mitochondrial diseases, fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Judit Molnar, MD, PhD to Senior Director of Translational Medicine with immediate effect. Judit has over ten […]

Mission Therapeutics Appoints Dr Bobby Soni to its Board of Directors

8th March 2018 in /by

CAMBRIDGE, UK – 8 March 2018 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Bobby Soni to its Board of Directors with immediate effect. Bobby replaces Rob Woodman as the representative for IP Group […]

Mission Therapeutics Strengthens Senior Management Team with Appointment of Dr Paul Thompson, Vice President, Clinical Development

1st March 2018 in /by

CAMBRIDGE, UK – 1 March 2018 – Today Mission Therapeutics, a drug discovery and development company focused on treating fibrosis, neurodegenerative and other diseases by selectively targeting deubiquitylating enzymes (DUBs), announced the promotion of Dr Paul Thompson to Vice President, Clinical Development with immediate effect. Dr Thompson has over 15 years’ experience in translational research […]

Mission Therapeutics’ Highlights Positive Parkinson’s Disease USP30 Target and Inhibitor Data at the Society for Neuroscience 2017 Annual Meeting

16th November 2017 in /by

CAMBRIDGE, UK –15 November 2017 – Mission Therapeutics, the leading drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, fibrosis, and other diseases with high unmet medical need, is presenting two posters with new research and preclinical data from its USP30 inhibitor Parkinson’s disease programmes today at Neuroscience […]